



(51) International Patent Classification:

A61P 11/00 (2006.01) *C07D 519/00* (2006.01)
A61K 31/50 (2006.01)

(21) International Application Number:

PCT/US2024/049813

(22) International Filing Date:

03 October 2024 (03.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/587,955 04 October 2023 (04.10.2023) US

(71) Applicant: VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 50 Northern Avenue, Boston, Massachusetts 02210 (US).

(72) Inventors: ABELA, Alexander Russell; 50 Northern Avenue, Boston, Massachusetts 02210 (US). CLEMENS, Jeremy; 50 Northern Avenue, Boston, Massachusetts 02210 (US). HADIDA RUAH, Sara Sabina; 50 Northern Avenue, Boston, Massachusetts 02210 (US). CLEVELAND, Thomas; 50 Northern Avenue, Boston, Massachusetts 02210 (US). COOK, Christopher Dean; 50 Northern Avenue, Boston, Massachusetts 02210 (US). COON, Timothy Richard; 50 Northern Avenue, Boston, Massachusetts 02210 (US). DINH, Andrew Nguyen; 50 Northern Avenue, Boston, Massachusetts 02210 (US). PIERRE, Fabrice; 50 Northern Avenue, Boston, Massachusetts 02210 (US). KHATUYA, Haripada; 50 Northern Avenue, Boston, Massachusetts 02210 (US). LEON MOS-TAJO, Brian; 50 Northern Avenue, Boston, Massachusetts 02210 (US). MILLER, Mark Thomas; 50 Northern Avenue, Boston, Massachusetts 02210 (US). MOTEVALLI, Somayeh; 50 Northern Avenue, Boston, Massachusetts 02210 (US). NANO, Adela; 50 Northern Avenue, Boston, Massachusetts 02210 (US). URSU, Oleg; 50 Northern Avenue, Boston, Massachusetts 02210 (US). UY, Johnny; 50 Northern Avenue, Boston, Massachusetts 02210 (US). ZHOU, Jinglan; 50 Northern Avenue, Boston, Massachusetts 02210 (US).

(74) Agent: MCDONELL, Leslie A et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

(57) Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies employing those modulators, and processes and intermediates for making such modulators.

WO 2025/076235 A1